NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equipment

Equipment

6 Months Ended

Jun. 30, 2023

Equipment

Equipment

4. Equipment

The Company’s equipment consisted of the following:


	As of June 30,		As of December 31,
	2023		2022
	Unaudited		Unaudited
Laboratory equipment	$	2,964,069	$	3,048,579
Office equipment		259,978		259,978
Leasehold improvements		31,405		17,958
Total		3,255,452		3,326,515
Accumulated depreciation and amortization		(1,746,325)		(1,392,415)
Equipment, net	$	1,509,127	$	1,934,100

Depreciation expense for the three months ended June 30, 2023 and 2022 was approximately $0.2 million and $0.2 million, respectively. Depreciation expense for the six months ended June 30, 2023 and 2022 was approximately $0.4 million and $0.4 million, respectively.